Advertisement

Operative ÜBerlegungen beim Familiôren Mammakarzinom

  • T. Bachleitner-Hofmann
  • S. Taucher
Chapter
  • 815 Downloads

Auszug

Etwa 5 – 10% aller Mammakarzinome sind hereditär bedingt durch autosomal-dominant vererbte Mutationen in den Genen
  • Breast cancer (BRCA) gene 1 und 2 (hereditäres Mammakarzinom-/Ovarialkarzinomsyndrom),

  • p53 (Li-Fraumeni-Syndrom),

  • Phosphatase and tensin homolog (pTEN; Cowden-Syndrom) sowie

  • Serine/threonine protein kinase 11 (STK11/LKB1; Peutz-Jeghers Syndrom).

Weitere 15 – 20% der Mammakarzinome treten familiär gehäuft, jedoch ohne autosomal-dominantes Vererbungsmuster auf und sind vermutlich durch das Zusammenwirken mehrerer genetischer Faktoren mit niedriger Penetranz bedingt (Lynch et al., 2003).

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Breast Cancer Linkage Consortium (1997) Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Lancet 349: 1505–1510CrossRefGoogle Scholar
  2. Claus EB, Risch N, Thompson WD (1994) Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction. Cancer 73: 643–651PubMedCrossRefGoogle Scholar
  3. Claus EB, Schildkraut JM, Thompson WD, Risch NJ (1996) The genetic attributable risk of breast and ovarian cancer. Cancer 77: 2318–2324PubMedCrossRefGoogle Scholar
  4. Eisen A, Rebbeck TR, Wood WC, Weber BL (2000) Prophylactic surgery in women with a hereditary predisposition to breast and ovarian cancer. J Clin Oncol 18: 1980–1995PubMedGoogle Scholar
  5. Fisher B, Costantino JP, Wickerham DL et al. (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90: 1371–1388PubMedCrossRefGoogle Scholar
  6. Ford D, Easton DF, Stratton M et al. (1998). Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 62: 676–689PubMedCrossRefGoogle Scholar
  7. Gabriel SE, Woods JE, O’Fallon WM, Beard CM, Kurland LT, Melton LJ (1997) Complications leading to surgery after breast implantation. N Engl J Med 336: 677–682PubMedCrossRefGoogle Scholar
  8. Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, Mulvihill JJ (1989) Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 81: 1879–1886PubMedCrossRefGoogle Scholar
  9. Grann VR, Jacobson JS, Thomason D, Hershman D, Heitjan DF, Neugut AI (2002) Effect of prevention strategies on survival and quality-adjusted survival of women with BRCA1/2 mutations: an updated decision analysis. J Clin Oncol 20: 2520–2529PubMedCrossRefGoogle Scholar
  10. Hartmann LC, Schaid DJ, Woods JE et al. (1999) Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 340: 77–84PubMedCrossRefGoogle Scholar
  11. Holzgreve W, Beller FK (1987) Surgical complications and follow-up evaluation of 163 patients with subcutaneous mastectomy. Aesthetic Plast Surg 11: 45–48PubMedCrossRefGoogle Scholar
  12. Kauff ND, Satagopan JM, Robson ME et al. (2002) Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346: 1609–1615PubMedCrossRefGoogle Scholar
  13. King MC, Wieand S, Hale K et al., National Surgical Adjuvant Breast and Bowel Project (2001) Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA 286: 2251–2256PubMedCrossRefGoogle Scholar
  14. Kuhl CK, Schrading S, Leutner CC et al. (2005) Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol 23: 8469–8476PubMedCrossRefGoogle Scholar
  15. Leach MO, Boggis CR, Dixon AK et al., MARIBS Study Group (2005) Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet 365: 1769–1778PubMedCrossRefGoogle Scholar
  16. Lynch HT, Snyder CL, Lynch JF, Riley BD, Rubinstein WS (2003) Hereditary breast-ovarian cancer at the bedside: role of the medical oncologist. J Clin Oncol 21: 740–753PubMedCrossRefGoogle Scholar
  17. Meijers-Heijboer H, van Geel B, van Putten WL et al. (2001) Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 345: 159–164PubMedCrossRefGoogle Scholar
  18. Metcalfe K, Lynch HT, Ghadirian P et al. (2004) Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 22: 2328–2335PubMedCrossRefGoogle Scholar
  19. Narod SA, Offit K (2005) Prevention and management of hereditary breast cancer. J Clin Oncol 23: 1656–1663PubMedCrossRefGoogle Scholar
  20. Narod SA, Brunet JS, Ghadirian P et al., Hereditary Breast Cancer Clinical Study Group (2000) Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet 356: 1876–1881PubMedCrossRefGoogle Scholar
  21. Narod SA, Foulkes WD (2004) BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer 4: 665–676PubMedCrossRefGoogle Scholar
  22. Payne DK, Biggs C, Tran KN, Borgen PI, Massie MJ (2000) Women’s regrets after bilateral prophylactic mastectomy. Ann Surg Oncol 7: 150–154PubMedCrossRefGoogle Scholar
  23. Phillips KA, Andrulis IL, Goodwin PJ (1999) Breast carcinomas arising in carriers of mutations in BRCA1 or BRCA2: are they prognostically different? J Clin Oncol 17: 3653–3663PubMedGoogle Scholar
  24. Powles T, Eeles R, Ashley S et al. (1998) Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 352: 98–101PubMedGoogle Scholar
  25. Rebbeck TR, Lynch HT, Neuhausen SL et al., Prevention and Observation of Surgical End Points Study Group (2002) Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346: 1616–1622PubMedCrossRefGoogle Scholar
  26. Rebbeck TR, Friebel T, Lynch HT et al. (2004) Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 22: 1055–1062PubMedCrossRefGoogle Scholar
  27. Schrag D, Kuntz KM, Garber JE, Weeks JC (1997) Decision analysis-effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. N Engl J Med 336: 1465–1471PubMedCrossRefGoogle Scholar
  28. Seynaeve C, Verhoog LC, van de Bosch LM et al. (2004) Ipsilateral breast tumour recurrence in hereditary breast cancer following breast-conserving therapy. Eur J Cancer 40: 1150–1158PubMedCrossRefGoogle Scholar
  29. Weitzel JN, McCaffrey SM, Nedelcu R, MacDonald DJ, Blazer KR, Cullinane CA (2003) Effect of genetic cancer risk assessment on surgical decisions at breast cancer diagnosis. Arch Surg 138: 1323–1328PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag / Wien 2007

Authors and Affiliations

  • T. Bachleitner-Hofmann
    • 1
  • S. Taucher
    • 2
  1. 1.Brustambulanz AKH Wien, Universitätsklinik für ChirurgieMedizinische Universität WienWien
  2. 2.BrustambulanzUniversitätsklinik für Frauenheilkunde InnsbruckInnsbruck

Personalised recommendations